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BACKGROUND AND PURPOSE
Matrix metalloproteinase (MMP) production from monocyte/macrophages is implicated in matrix remodelling and
modulation of inﬂammation. However, knowledge of the patterns and mechanisms of gene regulation of MMPs and their
endogenous tissue inhibitors (TIMPs) is fragmentary. MMP up-regulation may be a target for cyclooxygenase (COX) and
prostaglandin (PG) receptor inhibition, but the extent and mechanisms of COX-independent MMP up-regulation are unclear.
EXPERIMENTAL APPROACH
We studied MMP mRNA expression and selected protein levels in human peripheral blood monocytes before and after
adhesion, upon stimulation with bacterial lipopolysaccharide (LPS), PGE2 or forskolin and after culturing with monocyte
colony-stimulating factor on plastic or human ﬁbronectin for up to 7 days.
KEY RESULTS
Monocyte adherence for 2 h transiently up-regulated COX-2, MMP-1, MMP-7 and MMP-10 mRNAs, and persistently
up-regulated MMP-2, MMP-9, MMP-14 and MMP-19 mRNAs. LPS, PGE2 or forskolin selectively increased MMP-1, MMP-9,
MMP-10, MMP-12 and MMP-14 mRNAs. LPS increased PGE2 production through COX but up-regulated MMP levels
independently of COX. Differential dependence on inhibition of p42/44 and p38 mitogen-activated protein kinases, c-jun
N-terminal kinase and inhibitor of kB kinase2 paralleled the diverse patterns of MMP stimulation by LPS. Differentiation on
plastic increased mRNA levels of MMP-7, MMP-9, MMP-12 and MMP-14 and TIMP-2 and TIMP-3 independently of COX;
ﬁbronectin accelerated MMP but not TIMP up-regulation.
CONCLUSIONS AND IMPLICATIONS
Adhesion, LPS stimulation and maturation of human monocytes lead to selective, COX-independent MMP and TIMP gene
regulation, which is a potential target for selective inhibition by signalling kinase inhibitors.
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Introduction
Matrix metalloproteinases (MMPs) play an important part in
acute and chronic inﬂammation, partly by promoting turn-
over of the extracellular matrix (ECM) and partly by modulat-
ing the action of inﬂammatory mediators (Parks et al., 2004).
MMPs aid efﬁcient invasion of inﬂammatory cells to sites of
damage or infection, permit angiogenesis and prepare the
tissue for deposition of new ECM – all actions that ultimately
beneﬁt tissue repair (Parks et al., 2004). On the other hand,
excessive accumulation of ECM can lead to ﬁbrosis in such
tissues as the liver (Smart et al., 2001) and lungs (Taggart et al.,
2005). Conversely, excessive destruction of the ECM by MMPs
can lead to adverse consequences including the damage to
boneandcartilageinarthritis(Bakeret al.,2002)andtoseveral
ECM components in periodontal disease (Sorsa et al., 2006).
During atherosclerosis, destruction of the ECM can cause
weakening of the arterial wall, leading to aneurysm formation
(Shimizu et al., 2006) or atherosclerotic plaque rupture
(Newby, 2005) Hence, the ability to modulate MMP activity
andconsequentlyECMturnoverandinﬂammationcouldlead
to effective preventive treatments for several diseases.
The MMPs are a family of 23 genetically related Zn
2+-
dependent proteases (Nagase et al., 2006). There are also four
related tissue inhibitors of MMPs (TIMPs) that complex with
and inhibit the active enzymes (Nagase et al., 2006). Most
MMPs are secreted as pro-forms, which are then activated by
other proteases or chemical compounds in the ECM (Nagase
et al., 2006). The membrane-type MMPs are activated in the
endosomal compartment and then remain anchored to the
external membrane surface (Nagase et al., 2006). MMPs cleave
a variety of ECM substrates, and they have been divided
somewhat arbitrarily into collagenases, gelatinases, elastases
and stromelysins based on their preferred substrates, but
speciﬁcities overlap (Nagase et al., 2006). In addition, several
MMPs can activate the pro-forms of other MMPs, and many
MMPs also remodel cell surface and peri-cellular proteins,
which in turn regulate the migration, proliferation and apo-
ptosis of inﬂammatory and other cells (Parks et al., 2004;
Newby, 2006). Hence, the spectrum of MMPs and TIMPs
expressed as well as their absolute levels determine the extent
of ECM turnover and subsequent biological effects. However,
only one previous study measured a wide range of MMPs and
TIMPs in inﬂammatory cells (Bar-Or et al., 2003), and this
study provided limited information on MMP gene regulation.
MMP activity in monocytes is under transcriptional
control by growth factors, matrix contacts and inﬂammatory
mediators. Furthermore, up-regulation of several MMPs in
response to adhesion and bacterial lipopolysacharride (LPS)
can occur indirectly via the action of prostaglandin E2 (PGE2)
produced via cyclooxygenase (COX) activation (see Newby,
2008). As a result, COX inhibitors (Shankavaram et al., 2001;
Ardans et al., 2002; Khan et al., 2004) and antagonists at the
prostanoid EP4 receptor (Cipollone et al., 2005; Pavlovic et al.,
2006; nomenclature follows Alexander et al., 2009) prevent
MMP up-regulation experimentally and have therefore been
proposed as therapies to reduce damage to the ECM caused
during inﬂammation. However, COX-independent MMP-9
production was also reported in a one study (Zhang et al.,
1998), although the scope and relative magnitude of COX-
dependent and -independent responses was not clariﬁed.
Also, to our knowledge, there have been no previous publi-
cations regarding the mechanisms underlying COX-
independent regulation of MMPs.
We therefore set out to conduct a comprehensive study of
MMP and TIMP expression in human monocytes in the pres-
ence and absence of COX inhibitors under conditions that
mimic several processes likely to occur in the initial stages of
inﬂammation. These conditions included monocyte adhe-
sion, stimulation by LPS and differentiation to macrophages.
We also sought to deﬁne mechanisms for any COX-
independent regulation.
Methods
Monocyte puriﬁcation and culture conditions
Monocytes were isolated from buffy coats from healthy blood
donors, which were collected from National Blood Transfu-
sion Service (Bristol, UK) or from heparinized blood of healthy
volunteers under National Research Ethics Service approval
09/H0107/22 and 10/HO102/72, respectively. Mononuclear
cells were isolated using Ficoll–Paque Plus and contaminating
red blood cells were lysed with 150 mM ammonium chloride,
0.1% bovine serum albumin (BSA). Mononuclear cells were
allowed to adhere in RPMI 1640 supplemented with 2 mM
L-glutamine, 100 IU·mL
-1 penicillin, 100 mg·mL
-1 streptomy-
cin and 1% heat-inactivated human male AB serum at 7 ¥
10
5/cm
2 for 1 h in a humidiﬁed atmosphere containing 5%
CO2 at 37°C. The COX inhibitor indomethacin and the COX-
2-selective inhibitor NS-398 were included during adhesion
and throughout the experiment when used. Non-adherent
cells were removed with warm Dulbecco’s phosphate buffered
saline (DPBS), and the cells were transferred to RPMI contain-
ing 10% fetal bovine serum (FBS) for another hour. Where
indicated, wells were pre-coated with human plasma ﬁbronec-
tin at 0.05 mg·mL
-1 in DPBS by incubation for 1 h at room
temperature and overnight at 4°C and then blocking with
10 mg·mL
-1 fatty acid–free BSA for 2 h and two washes in
DPBS. CD16
- monocytes were puriﬁed from mononuclear
cells by negative selection using MACS
® monocyte isolation
kit II according to the manufacturer’s instructions. They were
either lysed or adhered as described for mononuclear cells as
required. Adherent monocytes were incubated in serum-free
RPMI 1640 for 18 h, and samples were collected for RNA, cell
lysates and conditioned medium. Monocyte maturation was
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indicated in the ﬁgure legends) and 20 ng·mL
-1 monocyte
colony-stimulating factor (MCSF) for 24 and 72 h followed by
18 h in serum-free RPMI 1640 to collect cell extracts and
conditioned medium. RNA was extracted after 42 and 72 h
and 7 days, respectively. Viability of the cells was conﬁrmed
by Trypan blue exclusion.
Real-time quantitative PCR
To quantify the steady-state concentration of mRNAs, total
RNA was extracted using RNeasy Mini kit (Qiagen, Crawley,
West Sussex, UK) according to the manufacturer’s instruc-
tions, quantiﬁed using a Nanodrop TM 1000 Spectrophotom-
eter (Thermo Fisher Scientiﬁc, Loughborough, Leicestershire,
UK) and reverse transcribed using a QuantiTect Reverse Tran-
scription Kit (100–200 ng RNA per reaction). A genomic DNA
removal step was included, and the resulting cDNA was
diluted 1:1 in 10 mM Tris–HCl, pH 8. Real-time quantitative
PCR was performed in a Roche Light Cycler 1.5 (Roche
Product Ltd, Welwyn Garden City, Hertfordshire, UK) to
quantify the steady-state concentration of RNA using a
Quanti Tect SYBR Green PCR Kit and primers as detailed in
Table S1. The reaction contained 3.6–7.3 ng RNA and 0.5 mM
primers. mRNA copy numbers were calculated using standard
curves constructed using the respective PCR products eluted
from agarose gels. All fragments were sequenced to conﬁrm
identity (Cogenics, Takely, UK).
Western blotting and zymography
Conditioned medium was collected and centrifuged at 270¥ g
for 3 min to remove cellular debris and was concentrated as
required using centrifugal ﬁlter units (Merck Chemicals, Not-
tingham, Nottinghamshire, UK). Cells were lysed in SDS
buffer (2% SDS (w/v), 16% glycerol (v/v) and 50 mM Tris (pH
6.8). Protein concentration in lysates was measured using
BCA Protein Assay Kit (Thermo Fisher Scientiﬁc) and was used
to normalize loading of gels. Samples from the ﬁbronectin
experiments were normalized by cell numbers: DNA content
in the cell lysates was measured using Picogreen (Molecular
Probes, Invitrogen, Paisley, Renfrewshire, UK); cell numbers
were calculated from a standard curve of human cell extracts.
Cell extracts and conditioned medium were diluted fourfold
in lysis buffer and reduced with 5% b-mercaptoethanol and
then fractionated by PAGE and analysed by Western blotting
as previously described (Chase et al., 2002). Detection was
performed using enhanced chemiluminescence (Merck
Chemicals).
MMP-9 metalloproteinase activity in conditioned
medium was evaluated by zymography as described (Chase
et al., 2002). Brieﬂy, 7.5% polyacrylamide gels containing
2 mg·mL
-1 gelatin were subjected to electrophoresis under
non-reducing conditions. Following electrophoresis, SDS was
removed by washing in 2.5% Triton X-100, and gels were
incubated at 37°C for 18 h in 50 mM Tris–HCl, pH 8.0,
50 mM NaCl, 10 mM Ca2Cl, and 0.05% Triton X-100. A par-
allel gel was incubated without CaCl2 in the presence of
10 mM EDTA. Gels were then stained in 0.2% Coomassie
Brilliant Blue. Gelatinase activity was detected as clear bands
on a dark background. Densitometric analysis of bands
was performed using scanner and Quantity One software
(Bio-Rad, Hemel Hempstead, Herts, UK).
PGE2 production
Culture supernatants from cells incubated for 24 h in 2% FBS
in RPMI 1640 were analysed for PGE2 production according to
manufacturer’s instructions.
Statistical analysis
Means were compared by ANOVA followed by appropriate post
tests. Normally distributed data are expressed as means 
s.e.mean. If any data were non-normally distributed, the
whole data set was subjected to non-parametric (Mann–
Whitney) testing. Alternatively, the data were log transformed
and if normalized was then tested by Student’s t-test with
correction for multiple testing. Non-normally distributed data
are expressed as means, and 95% conﬁdence intervals were
derived from the logarithmically transformed values.
Materials
Ficoll–Paque Plus (GE Healthcare, Little Chalfont, Bucking-
hamshire,UK)RPMI,FBS,DPBS(Lonza,Slough,Berkshire,UK)
MACS monocyte isolation kit II (Miltenyi Biotec, Bisley,
Surrey, UK). QuantiTect Reverse Transcription Kit and Quanti
Tect SYBR Green PCR Kit (Qiagen, Crawley, West Sussex, UK),
NS-398, SC514 and indomethacin (Cayman Chemicals, Cam-
bridge Bioscience Ltd, Cambridge, UK) were suspended in
DMSO except when otherwise stated. PD98059 (PD), SB20380
(SB) and SP600125 (SP) were obtained from Merck Chemicals
and dissolved in DMSO. Recombinant human MCSF and
Parameter PGE2 immunoassay™ to measure PGE2 release were
from R&D Systems (Abingdon, Oxon, UK). Fatty acid–free BSA
for cell treatments was obtained from Roche (Welwyn Garden
City, Hertfordshire, UK). LPS (E. coli 026:B6) and all other
reagents and primers were purchased from Sigma-Aldrich
(Gillingham,Dorset,UK).Thefollowingantibodieswereused:
MAPKs phospho and total were from New England Biolabs
(Hitchin, Hearts, UK), MMP-14 and GAPDH from Merck
Chemicals,MMP-10fromR&DSystems,COX-2andIkBafrom
Santa Cruz (Insight Biotechnology, Wembley, London, UK).
Results
MMP expression patterns in monocytes before
and after adhesion to plastic for 2–18 h
Adhesion is an early step in the recruitment of monocytes to
inﬂammatory foci and a prerequisite for their subsequent
differentiation to macrophages. We mimicked this using the
simplest protocol, namely adhesion to plastic in the presence
of serum. Pooled buffy coats, a convenient source of large
numbers of human primary monocytes and freshly drawn
blood, yielded indistinguishable results (not shown). Non-
adherent monocytes puriﬁed from buffy coats by negative
selection on magnetic beads had widely varying copy
numbers of mRNAs for MMPs and TIMPs (Figure 1, Table S2).
Based on mRNA levels, MMP-8, -9, -14 and -19 were the most
highly expressed in human monocytes, whereas MMP-1,
MMP-2, MMP-7, MMP-10, MMP-12 and MMP-23 were
expressed at very low levels. MMP-3 mRNA was undetectable.
Interestingly, the mRNAs of TIMP-1 and TIMP-2 were 10-fold
more abundant than any of the MMPs in non-adherent
BJP
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dant than the other TIMPs. Adherence of negatively selected
monocytes for 2 h increased mRNA levels of several MMPs
(Table S2). Negative selection removes the minority (approxi-
mately 10%) CD16
+ population of blood monocytes.
However, adhesion of non-selected mononuclear cells (CD16
+
and CD16
-) from buffy coats led to identical levels of MMP
and TIMP mRNAs as in negatively selected cells (Table S2).
Based on the pooled values from negatively selected and
non-selected mononuclear cells, MMP-1 was induced
approximately 6000-fold, MMP-2, 3-fold, MMP-7 from unde-
tectable, MMP-10, 900-fold, MMP-12, from undetectable,
MMP-14, 60-fold and MMP-19, 130-fold, whereas mRNA
levels of MMP-8, MMP-9 and MMP-23 did not change signiﬁ-
cantly compared with non-adherent cells (Figure 1, Table S2).
Copy numbers of mRNAs for TIMP-1 increased fourfold, but
expression of TIMP-2 and TIMP-3 was unchanged. Based on
mRNA levels, MMP-1, MMP-10, MMP-14 and MMP-19
became almost as abundant as TIMP-1 and TIMP-2 after adhe-
sion. In monocytes adhered to plastic for 18 h, mRNA levels
of MMP-1, MMP-7 and MMP-10, TIMP-1 and COX-1 and
COX-2 declined signiﬁcantly to values not statistically differ-
ent from non-adherent monocytes (Figure 1, Table S2).
Hence, adhesion caused a selective, transient up-regulation of
the mRNAs for these proteins.
Previous studies have concluded that MMP up-regulation
by adherent monocytes can be mediated indirectly by the
production of PGE2 mediated through COX. Consistent with
this COX-1 and COX-2 mRNAs were expressed in non-
adherent monocytes and were signiﬁcantly up-regulated
(fourfold and ninefold respectively) after adhesion for 2 h
(Figure 1, Table S2). Despite these increases in COX mRNA
levels, however, indomethacin (10 mM) had no effect on the
mRNA levels of any of the MMPs or TIMPs we studied
(Figure 2A).
Effects of LPS, PGE2 and forskolin on mRNA
expression after 18 h adhesion to plastic
Activation by Toll-like receptors (TLR) is also an early step in
monocyte activation, especially at sites of inﬂammation. In
order to model this mechanism, we designed experiments to
investigate the scope of MMP and TIMP regulation by LPS, a
TLR4 ligand, and its dependence on production of PGE2. LPS
strongly stimulated mRNA expression of MMP-1 (21-fold),
MMP-10 (44-fold) and MMP-14 (13-fold) and to a lesser
extent MMP-9 (2.3-fold) and TIMP-1 (3.1-fold) (Figure 2B).
Interestingly, the mRNA levels of neither MMPs nor TIMPs
were signiﬁcantly reduced by indomethacin (25 mM) treat-
ment (Figure 2A). These results implied, contrary to most
previous literature, that MMP mRNA expression changes
caused by LPS treatment were independent of PG synthesis.
We concluded that under the condition of our experiments,
the cells were either unresponsive to PGE2, or the levels of
PGE2 produced were too low to affect MMP and TIMP pro-
duction. However, we found that treating monocytes with a
maximal concentration of PGE2 (5 mM) increased MMP-1,
MMP-9, MMP-10 and MMP-14 and TIMP-1 and slightly
decreased TIMP-2 mRNA levels, showing that PGE2 largely
replicated the effects of LPS in our monocytes (Figure 2B).
Concentration response studies (results not shown) showed
that PGE2 increased mRNA levels of MMPs at above 50 nM.
Forskolin, a direct activator of adenylate cyclase, the down-
stream mediator of PGE2, also affected MMP and TIMP-1
mRNA levels (Figure 2B) to the same or greater extent com-
pared with LPS and PGE2 (Figure 2A, B). The effects on MMP-9
protein were conﬁrmed by zymography (inset in Figure 2B).
Hence, we concluded that LPS, PGE2 and cAMP elevation
were able to stimulate expression of several MMPs and
TIMP-1 in our preparations of monocytes.
We then demonstrated that LPS increased PGE2 levels
after 24 h to 3.1  0.9 nM from less than 0.2 nM (the limit of
detection) in our monocytes (Figure 2C). Furthermore, PGE2
production was reduced to 16  8% of the value with LPS
Figure 1
Copy numbers of mRNA per ng of RNA. Total RNA was extracted
from monocytes negatively selected on magnetic beads (CD16
-, n =
4–8) or after adhesion of these same cells or CD16
+/- mononuclear
cells for 2 h (n = 8–13) or 18 h (n = 8–15). Cell viability was >90%
after 2 h and >85% after 18 h. Complementary DNA was subjected
to quantitative PCR and compared with standards to calculate copy
numbers of mRNA per ng of RNA. (A) Results for several MMPs. (B)
Results for further MMPs, TIMPs, COX isoforms and CD206. Values
are means and upper 95 % conﬁdence intervals. **P < 0.01 2 h
adhesion versus non-adherent and 18 h adhesion; *P < 0.01 2 h
versus non-adherent only (Mann–Whitney); † not determined. For
more details see Table S2.
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to 35  12% by the COX-2 selective inhibitor, NS-398
(Figure 2C). Clearly, the concentrations of PGE2 obtained
under our experimental conditions were much lower than
the concentration necessary to stimulate MMP expression in
our preparations. Hence, the effects of LPS on MMP expres-
sion observed here were independent of COX and PGE2. From
our data, it is apparent that the COX- and PGE2-independent
LPS-mediated up-regulation of MMP-1, MMP-10, MMP-12
and MMP-14 mRNAs was as effective as maximal concentra-
tions of added PGE2. We therefore sought to investigate the
mechanisms underlying this COX-independent regulation.
Effects of mitogen-activated protein kinase
(MAP kinase) and inhibitor of kB kinase 2
(IKK2) inhibitors on LPS-induced MMP and
TIMP expression
MMP gene promoters contain proximal activator protein-1
(AP-1) and stimulator protein-1 (SP-1) transcription factor
binding sites that are known to be regulated by MAP kinases.
Up-regulation of MMPs may also depend directly or indi-
rectly on NF-kB (Vincenti and Brinckerhoff, 2002). We there-
fore investigated the ability of inhibitors of the ERK1/2 MAP
kinase activator MEK (PD98059), p38 MAP kinase activity
inhibitor (SB20380), c-jun N-terminal kinase (JNK) activity
inhibitor (SP600125) and the IKK2 inhibitor (SC514) on
adhesion or LPS-stimulated MMP and TIMP expression. To
determine appropriate concentrations for our studies, we ﬁrst
showed that LPS treatment activated MAP kinases in adher-
ent monocytes (Figure 3A, B). Adhesion also increased phos-
phorylation of ERK1/2, p38 and JNK (results not shown).
PD98059 inhibited LPS-induced ERK1/2 phosphorylation (by
83  6%) without effect on p38 or c-JUN phosphorylation
(Figure 3A, B). SB20380 activated ERK1/2 and JNK phospho-
rylation (192  36% and 151  27, Figure 3A, B), which is in
accord with previous reports (Birkenkamp et al., 2000; Hall
and Davis, 2002), but did not affect p38 phosphorylation as
expected, since it regulates p38 activity but not its phospho-
rylation by MKK3/6 or c-JUN phosphorylation. SP600125
inhibited JNK phosphorylation (98  1%, Figure 3A, B) via a
partial inhibition of MKK4 and an inhibition of JNK auto-
phosphorylation activity (Bennett et al., 2001), without
affecting p38 or ERK1/2 phosphorylation signiﬁcantly. The
ability of LPS to increase IKK2 activity was inferred from the
resulting (49  7%, n = 3) decrease in IkBa protein levels after
45 min (see Figure 3C) and the subsequent (5.2  1.0 fold,
n = 5) increase after 18 h in mRNA for I-kBa, which is tran-
scribed by NF-kB to restore quiescence (Baeuerle and Balti-
more, 1996). Adhesion for 2 h also increased IkBa mRNA
levels (3.7  1.2 fold, n = 3). Consistent with its known
activities (Kishore et al., 2003), SC514 inhibited the LPS
induced decrease in IkBa protein back to 84  9% (n = 3) of
untreated controls (see Figure 3C) and reduced the increase in
IkBa mRNA levels after adhesion or LPS treatment by 52  3
and 74  4% (n = 5), respectively.
The effects of the MAP kinase and IKK2 inhibitors were
then measured on MMP and TIMP expression. Indomethacin
was present throughout the LPS treatment to inhibit any
contribution from PGs. These series of experiments were
expanded to include measurements of MMP-7 and COX-1
and COX-2 mRNAs. LPS signiﬁcantly increased expression of
MMP-1, MMP-7, MMP-9, MMP-10 and MMP-14, TIMP-1,
COX-2 mRNAs but not TIMP-2, TIMP-3 or COX-1 (Figure 4).
The results were similar to the series of experiments shown in
Figure 2B conducted in the absence of indomethacin. The
Figure 2
Effects of LPS and indomethacin on mRNAs for MMPs and TIMPs and
PGE2 levels. (A) Effect of addition of indomethacin during adherence
(10 mM, n = 3) or LPS treatment (25 mM, n = 6–10) expressed as a
percentage of the values without indomethacin. (B) Fold change in
mRNA levels caused by adding 100 ng·mL
-1 LPS, 5 mM PGE2 or
50 mM forskolin to CD16
+/- monocytes for 18 h in serum-free
medium after 2 h of adhesion. Values are means and upper 95 %
conﬁdence intervals. *P < 0.05 versus no addition by ANOVA with
Dunnett’s post test (n = 6–10). Inset – protein levels of MMP-9 by
zymography after treatment with ethanol (E), DMSO (D), PGE2 (PG)
or forskolin (For). (C) PGE2 concentration was measured in condi-
tioned media under the conditions shown above and in the presence
of 100 ng·mL
-1 LPS, 25 mM indomethacin (indo) or 10 mM NS-398
(NS) as shown. The ﬁnal concentration of vehicle (DMSO) was 0.1%
v/v. Values are means  SEM. *P < 0.05 versus LPS. ANOVA with
Dunnett’s post test (n = 3).
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were conﬁrmed by Western blotting or zymography (inset).
As illustrated in Figure 5A–D, the MEK inhibitor,
PD98059, signiﬁcantly inhibited MMP-1, MMP-10, MMP-14
and COX-2 expression after adhesion or LPS treatment
(Figure 5A). The only consistent effect of the p38 inhibitor,
SB20380, between adhesion and LPS treatment was to
decrease COX-2 expression (Figure 5B). SB20380 reduced
MMP-7 but increased MMP-10 expression after LPS treatment
alone (Figure 5B). The JNK inhibitor, SP600125, consistently
reduced MMP-1, and MMP-10, and COX-2 but increased
TIMP-3 mRNA levels on adhesion and LPS treatment;
MMP-14 was reduced only after adhesion (Figure 5C).
SP600125 slightly increased MMP-7 mRNA levels after adhe-
sion and MMP-9 mRNA levels after LPS treatment. Protein
expression studies conﬁrmed the small effects of PD98059
and SP600125 on MMP-9 and much more pronounced effects
on MMP-10 protein levels (Figure S1A). The IKK2 inhibitor,
SC514, also consistently decreased MMP-1, MMP-10 and
MMP-14 and COX-2 mRNA levels after adhesion and LPS
treatment. Taken together our results clearly showed regula-
tion of MMP-1, MMP-10 and MMP-14 depended on ERK1/2
and JNK MAP kinases and IKK2, but the other MMP and TIMP
genes we studied did not.
MMP and TIMP expression during
differentiation on plastic or ﬁbronectin
After entering the blood vessel wall, monocytes differentiate
to macrophages. To model this transformation, we studied
monocytes from buffy coats during adhesion to plastic with
M-CSF for 7 days. As summarized in Table S2, no differences
were seen between un-fractionated and CD16- monocytes
(Table S2). To conﬁrm differentiation, we showed that the
marker gene CD206 did not change on adhesion (Figure 1,
Table S2) but was dramatically increased 108-fold during
culture with M-CSF (Table S2). Differentiation with M-CSF for
7 days led to a fall in MMP-1 (332-fold), MMP-10 (190-fold),
TIMP-1 (7.5-fold) and COX-2 (353-fold) mRNA levels but an
increase in expression of MMP-7 (126-fold), MMP-9 (139-
fold), MMP-12 (4.4-fold) and MMP-14 (3.5-fold) and of
TIMP-2 (2.8-fold) and especially TIMP-3 (347-fold) (Table S2).
MMP-8 and MMP-23 and COX-1 mRNA levels were not sig-
niﬁcantly changed during differentiation (Table S2). More
detailed time-courses compared monocytes adhered either to
plastic or ﬁbronectin, as a model for the intimal extracellular
matrix, as measured over the ﬁrst 72 h. These independent
experiments conﬁrmed that mRNA levels of MMP-1
(Figure 6A) declined during differentiation on plastic or
ﬁbronectin, although the initial increase after 2 h was signiﬁ-
cantly attenuated by ﬁbronectin. By contrast, expression of
MMP-7 (Figure 6B), MMP-9 (Figure 6C), MMP-12 (Figure 6D)
and MMP-14 (Figure 6E) increased progressively. Binding to
ﬁbronectin accelerated the increase in expression of MMP-7,
Figure 3
Effects of inhibitors of MAP kinase and IKK2 on kinase activities.
Adherent monocytes were pre-treated with the inhibitors for 45 min
before addition of 100 ng·mL
-1 LPS in serum-free medium. MAP
kinase inhibitors: PD98059 (PD), SB20380 (SB) and SP600125 (SP)
were all added at 10 mM and the IKK2 inhibitor SC514 at 40 mMi n
0.1% v/v DMSO. (A) Effects of MAP kinase inhibitors on LPS
(100 ng·mL
-1)-stimulated ERK, p38 MAP kinase and JNK phosphory-
lation by Western blotting. LPS was added for 45 min. (B) Densito-
metry of Western blots represented in panel A (n = 4–6). *P < 0.05
versus LPS alone. (C) A representative of three similar Western blots
for IkBa showing depletion by LPS and restoration by 40 mM SC514.
Figure 4
LPS effects in the presence of indomethacin. Stimulation of mRNAs
(as fold increase) by 100 ng·mL-1 LPS for 18 h with 25 mM
indomethacin present. Values are means and upper 95 % conﬁdence
intervals. *P < 0.05 versus no addition of LPS. ANOVA with Dunnett’s
post test on log-transformed data (n = 6–10). Inset – protein levels
with (right-hand lanes) and without (left-hand lanes) LPS measured
by Western blotting or zymography for MMP-9.
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MMP-12 was not statistically signiﬁcant (Figure 6D).
Increased expression of MMP-12 and MMP-14 appeared
delayed compared with MMP-7 and MMP-9. The effect of
ﬁbronectin on MMP-9 was conﬁrmed at the protein level by
zymography (Figure S1B). In agreement with the mRNA data
(Figure 6C), MMP-9 protein was signiﬁcantly increased to 154
 12% (P < 0.05, n = 3) after 42 h of adhesion to ﬁbronectin
compared with plastic. Expression of TIMP-1 declined pro-
gressively (Figure 6F), while TIMP-2 (Figure 6G) and espe-
cially TIMP-3 (Figure 6H) progressively increased; TIMP
expression was not modiﬁed by ﬁbronectin. None of the
increases in MMP or TIMP mRNA expression were decreased
by indomethacin or NS-398. For example, MMP mRNA
expression was 72  16% (n = 6) in the presence of
indomethacin and 200  73% in the presence of NS-398 (n =
5). Protein expression of MMP-9 was also unaffected by
indomethacin (96  7%, n = 5; Figure S1C) or NS-398 (180 
21%, n = 5; not shown in Figure S1C). Hence, we concluded
that the increased expression of MMPs and TIMPs during
maturation of monocytes to macrophages is also indepen-
dent of COX under the conditions we used. The expression of
MMP, TIMP and COX-1 mRNAs were not affected by incuba-
tion of differentiated macrophages with inhibitors of ERK1/2,
p38 or JNK MAP kinases for the ﬁnal 48 h (Table S3). By
contrast, inhibition of ERK1/2 and JNK decreased COX-2
mRNA levels by approximately 50% (Table S3).
Discussion
We studied the expression of a wide range of MMPs and TIMPs
in monocytes after adhesion, treatment with LPS and differ-
entiationintomacrophages,thusmimickingeventsthatoccur
early in inﬂammation. We then investigated the potential
mechanisms responsible for the diverse pattern of MMP and
TIMP regulation. Our study used human primary blood-
derived monocytes rather than a cell line, thus allowing for a
cautious extrapolation to inﬂammatory events in vivo.
In agreement with previous work (Bar-Or et al., 2003), the
most abundant MMP transcripts in adherent monocytes
were MMP-1, MMP-7, MMP-8, MMP-9, MMP-10, MMP-14
and MMP-19. Interestingly, however, our data demonstrated
that MMP-1, MMP-7 and MMP-10 were almost absent in
Figure 5
Effects of MAP kinase and IkB kinase2 inhibitors. Total mononuclear cells were pre-treated in suspension for 20 min at 37°C with the inhibitors
shown or vehicle before adhering in 1% AB serum followed by 10% FBS always in the presence of the inhibitors for 2 h (adhesion). Alternatively,
adherent monocytes were pre-treated in serum-free medium with the inhibitors for 45 min before addition of 100 ng·mL
-1 LPS for 18 h in
serum-free medium (LPS). (A) Levels of mRNA with 10 mM PD98059 present. *P < 0.05 versus adhesion or addition of LPS alone. ANOVA with
Dunnett’s post test (n = 5). (B) As above with 10 mM SB20380. (C) As above with 10 mM SP600125. (D) As above with 40 mM SC514.
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induced by adherence. Hence, only MMP-8, MMP-9, MMP-14
and MMP-19 mRNAs were constitutively expressed at high
levels in non-adhered monocytes, which presumably reﬂect
circulating monocytes. Adhesion rapidly increased mRNAs
for several MMPs including MMP-1 and MMP-10 that could
aid monocyte migration into areas of inﬂammation. No pre-
vious study has, to our knowledge, addressed the impact of
monocyte subsets on the proﬁles of MMP expression
observed. We found similar patterns of expression when
using mixed CD16
+ and CD16
- and negatively selected CD16
-
monocytes (Table S2), and therefore, no evidence of selective
up-regulation of MMPs in the minority CD16
+ population. All
the results we observed were dominated by the majority
CD16
- population.
The ability of LPS to increase expression of MMP-1,
MMP-9 and MMP-14 and TIMP-1 has been previously
reported (Shankavaram et al., 2001; Ardans et al., 2002).
However, no previous study has simultaneously studied a
large number of MMPs and TIMPs. Our study showed that
LPS treatment of monocytes up-regulated two collagenases,
MMP-1 and MMP-14 (a membrane-type MMP), a gelatinase
(MMP-9), two stromelysins, MMP-7 and MMP-10, and the
metalloelastase, MMP-12. Among the TIMPs, only TIMP-1
was up-regulated, which implies a strong increase in the
MMP/TIMP balance. The substrate components of the MMPs
up-regulated by LPS include most constituents of the ECM,
which suggests a potentially high destructive power of
recently recruited monocytes activated by bacterial products
at a site of an infection.
Figure 6
Time course of changes in MMP and TIMP mRNAs during CD16+/- monocyte differentiation on plastic and ﬁbronectin. Fold changes in MMP and
TIMP mRNAs levels relative to values for 2 h adhesion. Values are means and upper 95 % conﬁdence intervals. *P < 0.05 ﬁbronectin versus plastic.
†P < 0.05 both ﬁbronectin and plastic versus 2 h adhesion. ANOVA with Dunnett’s post test on log-transformed data (n = 4). (A) MMP-1, (B)
MMP-7, (C) MMP-9, (D) MMP-12, (E) MMP-14, (F) TIMP-1, (G) TIMP-2, (H) TIMP-3.
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ages had a very different effect on MMP and TIMP expression
compared with adherence or LPS treatment (see Figure 7).
Expression of the collagenases MMP-1 and its activator
MMP-10 (Saunders et al., 2005), as well as COX-2, which were
increased by adhesion and LPS treatment, were greatly
reduced during maturation. Conversely, the gelatinases
MMP-2 and MMP-9, the stromelysin MMP-7 and the metal-
loelastase MMP-12 were all greatly increased by LPS and dif-
ferentiation (Figure 1, Table S2). Since MMP-10 is a preferred
activator of MMP-1 (Saunders et al., 2005), it appears that
mature, unstimulated macrophages may have a reduced
capacity to remodel ﬁbrillar collagen but an increased capac-
ity to turn over other ECM components. However, this
increased potential for matrix turnover could be counteracted
by increased TIMP-2 and TIMP-3 expression, the latter effect
having already been reported (Fabunmi et al., 1998). Interest-
ingly, TIMP-3 expression was not up-regulated by adhesion or
LPS, but cellular differentiation caused an increase greater
than for any other of the genes examined. Binding of TIMP-3
to the ECM would tend to encapsulate mature macrophages
and protect the ECM from further proteolysis.
Fibronectin is an abundant component of the ECM that is
synthesized by macrophages in culture. Indeed, ﬁbronectin
is one of the most up-regulated genes during macro-
phage differentiation (Lehtonen et al., 2007). Fibronectin is
also increased during inﬂammation in vivo (Stecher et al.,
1986, Feaver et al., 2010). Fibronectin was previously shown
to up-regulate expression of MMP-9 and MMP-14 in human
monocytes (Jacob et al., 2002; Matias-Roman et al., 2005). We
found here that culturing on ﬁbronectin actually accelerated
expression of MMP-7, MMP-9 and MMP-14 during differen-
tiation without affecting ﬁnal expression levels after 4 days.
Fibronectin did not inﬂuence TIMP expression. Hence,
binding to ﬁbronectin would be expected to increase the ratio
of MMPs to TIMPs and favour ECM degradation in the early
stages of monocyte to macrophage transformation in vivo.
Perhaps most interestingly, our new ﬁndings demonstrate
that the magnitude and scope of COX-independent MMP
regulation is much greater than previously appreciated.
Indeed, up-regulation of MMP-1, MMP-7, MMP-9, MMP-10,
MMP-12 and MMP-14 in human monocytes by adhesion, LPS
treatmentordifferentiationtomacrophageswithMCSFcanall
occurbyCOX-independentmechanisms.Thisﬁndingappears
to contradict much previous work, which convincingly dem-
onstrated the existence of a PG-dependent pathway of MMP
up-regulation in human and mouse monocytes, even though
a COX-independent regulation of MMP-9 and TIMP-1 by
cytokines had been reported in one publication (Zhang et al.,
1998). In our study, we conﬁrmed previous results that LPS
induced COX-2 and PGE2 production (Ardans et al., 2002;
Khan et al., 2004). Furthermore, we also conﬁrmed previous
observations that MMP up-regulation can be mimicked by
adding PGE2 (Corcoran et al., 1992; Shankavaram et al., 2001)
or forskolin (Pavlovic et al., 2006), a direct activator of adeny-
late cyclase. Hence, the whole pathway from LPS to PGE2 and
from PGE2 to MMP up-regulation is present in monocytes.
However,wefoundthatMMPexpressioncouldnotbeblocked
by a non-selective COX inhibitor under the conditions of our
experiments, which is in contrast to previous work (Shanka-
varam et al., 2001; Ardans et al., 2002; Khan et al., 2004). This
apparent disagreement was resolved by showing that PGE2
levels did not accumulate sufﬁciently to trigger MMP induc-
tion in our experiments. Previous work showed that at least
10–100 nM PGE2 is required to elicit an effect on MMP
up-regulation even in monocytes co-stimulated with other
agonists (Corcoran et al., 1992; Shankavaram et al., 2001;
Khan et al., 2004). Our dose–response studies were in broad
agreement, whereas only 3 nM PGE2 accumulated under the
conditions of our experiments (Figure 2C). These conditions
therefore revealed the existence of COX-independent path-
ways capable of up-regulating MMPs and TIMP-1 at least as
effectively as the PGE2-dependent pathways. Both COX-
dependent and -independent pathways are likely to be impor-
Figure 7
Summary of changes in MMP, TIMP and COX-2 mRNA levels. The table summarizes fold changes relative to the controls shown (see other ﬁgures
for details). Red and blue numbers show increases and decreases, respectively.
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much higher close to a focus of inﬂammation than in our in
vitro cultures. However, prostaglandin-independent pathways
ofmonocyteandmacrophageMMPproductionwouldremain
active during treatment with COX inhibitors in vivo, and this
would limit the effectiveness of these agents in treating the
adverse ECM remodelling that occurs during inﬂammation.
Such concerns have gained added importance in the wake of
clinical trial data showing no beneﬁt or harm from COX-2
inhibitor treatment in the context of symptomatic cardiovas-
cular disease (Cipollone et al., 2008).
In attempting to identify mechanisms for the COX-
independent up-regulation of MMPs, we noted that the pro-
moters of MMP-1, MMP-7, MMP-9, MMP-10 and MMP-12
and TIMP-1 all have essential, proximal AP-1 sites that bind
Fos and Jun family transcription factors (Benbow and Brink-
erhoff, 1997). Moreover, MAP kinases have been extensively
implicated in AP-1 transcription factors and MMP
up-regulation in other cell types (Vincenti and Brinckerhoff,
2002; Chakraborti et al., 2003). Furthermore, a role for NF-kB
in up-regulation of some MMPs has been clearly identiﬁed,
including in monocyte/macrophages (Chase et al., 2002; Vin-
centi and Brinckerhoff, 2002). Interestingly, adhesion and
LPS-induced, COX-independent up-regulation of different
MMPs and TIMPs showed a diverse pattern of dependence on
activation of MAP kinases and NF-kB (see Figure 7). The ﬁrst
pattern was exempliﬁed by MMP-1 and -10 (and COX-2) that
were strongly up-regulated by adhesion and LPS treatment
but decreased during maturation. Expression of these was
strongly dependent on activation of ERK1/2, JNK and IKK2
(Figure 7). Up-regulation of MMP-10 only by the p38 MAP
kinase inhibitor SB20380 (Figure 5B) could be explained by
its ability to increase ERK1/2 phosphorylation (Birkenkamp
et al., 2000; Hall and Davis, 2002), as we conﬁrmed
(Figure 3A). The pattern of regulation of MMP-14 showed
some similarity to MMP-1 and MMP-10, although the proxi-
mal promoter of the MMP-14 gene depends on an SP-1 rather
than an AP-1 binding site (Lohi et al., 2000). MMP-14 was
up-regulated in response to adhesion dependent on ERK1/2,
JNK and IKK2 activity and by LPS dependent on ERK1/2, and
IKK2 activity only (Figure 7). The biggest difference was that
MMP-14 expression increased rather than decreased during
differentiation (Figure 7). MMP-7, MMP-9 and TIMP-1
showed another pattern; they were up-regulated by adhesion,
LPS treatment and differentiation largely independently of
ERK1/2, JNK and IKK2 (Figure 7). MMP-7 only showed a
dependence on p38 MAP kinase activity after LPS treatment
(Figure 7). Finally, TIMP-2 and TIMP-3 expression was not
increased by adhesion or LPS and was independent of MAP
kinases or IKK2. None of the MAP kinase inhibitors affected
MMP or TIMP production from un-stimulated mature mac-
rophages (Table S3). This was expected in the case of MMP-1
and MMP-10, which were already down-regulated after dif-
ferentiation, but it underlines the fact that distinct pathways
must be responsible for the up-regulation of MMP-14 by LPS
and differentiation.
In summary, we found that adhesion and LPS-treatment
of CD16
- and CD16
+/- monocytes selectively increased the
steady-state mRNA levels of MMP-1, MMP-7, MMP-9,
MMP-10 and MMP-14 to a greater degree than TIMPs, imply-
ing a shift in the protease/anti-protease balance in favour of
matrix degradation. Differentiation into macrophages down-
regulated MMP-1 and MMP-10 but increased MMP-7, MMP-9,
MMP-12 and MMP-14 and TIMP-3 mRNAs. The effects on
MMP and TIMP during adhesion, LPS treatment and differ-
entiation were independent of PGE2 production through
COX. Only MMP-1, MMP-10 and MMP-14 up-regulation by
adhesion and LPS treatment depended on ERK1/2, JNK or
IKK2 activation. These results may have important implica-
tions for the pharmacological inhibition of MMP production
and hence the mitigation of ECM degradation during acute
and chronic inﬂammation.
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